OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut

Genders: All
Ages: 18 - 55
Phase 1
Contact this research center for additional information
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Brief Summary

This is a phase 1, multi-center, randomized, double-blind, placebo-controlled study in adult participants with peanut allergy. Participants will be randomized in a 3:1 ratio to receive either an escalating dose of INT301 or placebo. The treatment group will be blinded to the investigator, participants, and the Intrommune study team. Identifier: NCT04603300
Recruitment Status: Active, not recruiting
First Posted: 10/26/2020
Last Update Posted: 10/18/2022


Drug: INT301 / INT301 is an allergy immunotherapy delivered in the form of a fully functional toothpaste.

Drug: Placebo / Fully functional toothpaste containing no immunotherapy agents.

You may be eligible to join if...
  • Participant must be 18-55 years of age inclusive, at the time of signing the informed consent.
  • Female participants of childbearing potential or male participants with female partners of child-bearing potential must utilize highly effective birth control method(s) throughout the study and for 30 days after the final dose of study drug. Acceptable methods of contraception include: complete abstinence, male or female condoms with spermicide, oral or implanted contraceptives, or vasectomy.
  • For female participants of child-bearing potential: Negative serum beta human chorionic gonadotrophin (HCG) pregnancy test at screening.
  • Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Meets at least one of the following conditions
  • Positive skin prick test (SPT) (wheal at least 3 mm greater than control) AND/OR Peanut specific IgE >0.35 kU/L
  • Convincing clinical history of allergic reaction to peanut within 1 hour of ingestion for at least 3 months prior to screening.
  • Failed an oral food challenge (OFC) of < 100mg of peanut protein at screening.
  • Participant willing and able to undergo the procedures required by the protocol, including, assessment completion, protocol compliance, and participation in the placebo dosing period(s).
You may not be eligible to join if...
  • History of severe anaphylaxis to peanut, defined as hypoxia, hypotension, or neurologic compromise (cyanosis or oxygen saturations < 92% at any stage, hypotension, confusion, collapse, loss of consciousness, or incontinence)
  • Planned dental surgery during from screening until study exit
  • Moderate or advanced periodontal disease.
  • Current pregnancy or lactating
  • Significant medical condition (e.g., liver, kidney, gastrointestinal, cardiovascular, hematologic, or pulmonary disease) which would make the subject unsuitable for induction of food reactions
  • Eosinophilic or other inflammatory (e.g. celiac) gastrointestinal disease
  • Psychiatric disorders that the Investigator believes will interfere with study assessments
  • Uncontrolled asthma, defined by at least one of the following conditions:
  • - FEV1 <80% of predicted, or ratio of FEV1 to forced vital capacity (FEV1/FVC) <75% of predicted, with or without controller medications.
  • - Inhaled corticosteroids (ICS) dosing of >500mcg daily fluticasone (or equivalent ICS based on NHLBI dosing chart.
  • - One hospitalization in the past year for asthma
  • - An ER visit for asthma within six months prior to screening

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Information may not constitute the most up-to-date trial information. Read our disclaimer for details.

Go to >